SuperworthMAIA Biotechnology price to book ratio MAIA
Market value divided by the book value of the company's net assets, since 2022.
- Today, Oct 23, 2026
- 3.4×
- 4-year median
- 6.6×
- Against its 4-year history
- 15th
- percentile: 0 is its lowest day, 100 its highest
- 4-year range
- 2.7× to 137×
- Peer median
- 1.5×
MAIA Biotechnology's price to book ratio is 3.4× as of Oct 23, 2026.
That is below its 4-year median of 6.6×, lower than on 85% of days in the last 4 years.
Over that time it ranged from 2.7× in Jul 2026 to 137× in May 2024.
The median for 9 large drugmakers of a similar size is 1.5×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 3.4× | 2.7× | 34.5× |
| 2025 | 9.5× | 9.3× | 34.9× |
| 2024 | 32.7× | 5.7× | 137× |
| 2023 | 6.1× | 3.0× | 10.3× |
| 2022 | 3.1× | 3.0× | 7.0× |
Against its peers
Companies in Drug Manufacturers - General nearest MAIA Biotechnology's size, closest first, today.
| Company | Price to book ratio |
|---|---|
| MAIAMAIA Biotechnology | 3.4× |
| LFVNLifevantage | 2.2× |
| SPROSpero Therapeutics | 1.5× |
| ATNMActinium Pharmaceuticals | 1.6× |
| NATRNatures Sunshine Products | 1.3× |
| ARVNArvinas | 0.8× |
| PBYIPuma Biotechnology | 4.1× |
| IRWDIronwood Pharmaceuticals | n/m |
| ZVRAZevra Therapeutics | 2.7× |
| CRMDCorMedix | 1.3× |
| Peer median | 1.5× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on MAIA Biotechnology
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.